COVID-19 Vaccination in Inflammatory Bowel Disease (IBD)
Vaccines against SARS-CoV-2 are believed to play a key role in the suppression of the COVID-19 pandemic. However, patients suffering from inflammatory bowel diseases (IBD) were excluded from SARS-CoV-2 vaccines trials. Therefore, concerns regarding vaccination efficacy and safety among those patient...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/9/2676 |
| _version_ | 1797504127324913664 |
|---|---|
| author | Aleksandra Kubas Ewa Malecka-Wojciesko |
| author_facet | Aleksandra Kubas Ewa Malecka-Wojciesko |
| author_sort | Aleksandra Kubas |
| collection | DOAJ |
| description | Vaccines against SARS-CoV-2 are believed to play a key role in the suppression of the COVID-19 pandemic. However, patients suffering from inflammatory bowel diseases (IBD) were excluded from SARS-CoV-2 vaccines trials. Therefore, concerns regarding vaccination efficacy and safety among those patients were raised. Overall, vaccination is well tolerated in the IBD population, and different gastroenterological societies recommend vaccinating patients with IBD at the earliest opportunity to do so. Nevertheless, very little is known about the safety of COVID-19 vaccines in special IBD populations such as pregnant and breastfeeding women or pediatric patients, and further research on this matter is crucial. The available data on vaccine efficacy are promising and show high seroconversion rates in IBD patients on different immune-modifying therapies. However, patients treated with high doses of systemic corticosteroids, infliximab or infliximab and immunomodulators may have a blunted response to the vaccination. The data on COVID-19 vaccination willingness among patients with IBD are conflicting. Nevertheless, vaccine effectiveness and safety are reported to be the most common reasons for hesitancy. This review examines the effectiveness and safety of COVID-19 vaccines and describes vaccination willingness and the reasons for potential hesitancy among patients with IBD. |
| first_indexed | 2024-03-10T04:00:14Z |
| format | Article |
| id | doaj.art-32509d26e70846c9a1bdfb3b61ff9a28 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T04:00:14Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-32509d26e70846c9a1bdfb3b61ff9a282023-11-23T08:35:53ZengMDPI AGJournal of Clinical Medicine2077-03832022-05-01119267610.3390/jcm11092676COVID-19 Vaccination in Inflammatory Bowel Disease (IBD)Aleksandra Kubas0Ewa Malecka-Wojciesko1Department of Digestive Tract Diseases, Medical University of Lodz, Kopcinskiego 22, 90-153 Lodz, PolandDepartment of Digestive Tract Diseases, Medical University of Lodz, Kopcinskiego 22, 90-153 Lodz, PolandVaccines against SARS-CoV-2 are believed to play a key role in the suppression of the COVID-19 pandemic. However, patients suffering from inflammatory bowel diseases (IBD) were excluded from SARS-CoV-2 vaccines trials. Therefore, concerns regarding vaccination efficacy and safety among those patients were raised. Overall, vaccination is well tolerated in the IBD population, and different gastroenterological societies recommend vaccinating patients with IBD at the earliest opportunity to do so. Nevertheless, very little is known about the safety of COVID-19 vaccines in special IBD populations such as pregnant and breastfeeding women or pediatric patients, and further research on this matter is crucial. The available data on vaccine efficacy are promising and show high seroconversion rates in IBD patients on different immune-modifying therapies. However, patients treated with high doses of systemic corticosteroids, infliximab or infliximab and immunomodulators may have a blunted response to the vaccination. The data on COVID-19 vaccination willingness among patients with IBD are conflicting. Nevertheless, vaccine effectiveness and safety are reported to be the most common reasons for hesitancy. This review examines the effectiveness and safety of COVID-19 vaccines and describes vaccination willingness and the reasons for potential hesitancy among patients with IBD.https://www.mdpi.com/2077-0383/11/9/2676inflammatory bowel diseaseCOVID-19 vaccinationbiologic therapyvaccine safetyvaccine effectivenessvaccination willingness |
| spellingShingle | Aleksandra Kubas Ewa Malecka-Wojciesko COVID-19 Vaccination in Inflammatory Bowel Disease (IBD) Journal of Clinical Medicine inflammatory bowel disease COVID-19 vaccination biologic therapy vaccine safety vaccine effectiveness vaccination willingness |
| title | COVID-19 Vaccination in Inflammatory Bowel Disease (IBD) |
| title_full | COVID-19 Vaccination in Inflammatory Bowel Disease (IBD) |
| title_fullStr | COVID-19 Vaccination in Inflammatory Bowel Disease (IBD) |
| title_full_unstemmed | COVID-19 Vaccination in Inflammatory Bowel Disease (IBD) |
| title_short | COVID-19 Vaccination in Inflammatory Bowel Disease (IBD) |
| title_sort | covid 19 vaccination in inflammatory bowel disease ibd |
| topic | inflammatory bowel disease COVID-19 vaccination biologic therapy vaccine safety vaccine effectiveness vaccination willingness |
| url | https://www.mdpi.com/2077-0383/11/9/2676 |
| work_keys_str_mv | AT aleksandrakubas covid19vaccinationininflammatoryboweldiseaseibd AT ewamaleckawojciesko covid19vaccinationininflammatoryboweldiseaseibd |